Beta Bionics, Inc. — Form 8-K
Filed July 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Beta Bionics reported Q2 2026 net sales of $32.0M (up 38% YoY from $23.2M), with gross margin expanding 524 bps to 59.0%. PBP channel sales surged 153% to $11.6M. However, net loss widened to $23.4M (73% of sales) from $16.9M, and adjusted EBITDA remained deeply negative at −$17.7M (−55% of sales). Cash position of $225.2M; full-year 2026 revenue guidance unchanged at $131M–$136M. Key pipeline milestones: iLet Type 2 diabetes trial initiated, Mint patch pump commercialization expected Q2 2027.
Why this rating
Strong revenue growth and margin expansion are offset by persistent, worsening operating losses. Cash reserves ($225.2M ≈ 36% of market cap) provide runway, but burn rate (~$70M annualized) demands near-term profitability. Pipeline progress (Type 2 diabetes, Mint) offers upside but remains contingent on FDA approval and market adoption. Relative to $632M market cap, growth trajectory is encouraging but losses remain substantial. Neutral reflects balanced risk/opportunity.
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.